Please assess the completion status of the following clinical trial:

Trial Title: A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Primary Inclusion Criteria~1. Have completed the LBSL02 trial and achieved a satisfactory response.~Primary Exclusion Criteria~1. Required more than 2 courses of corticosteroids for treatment of severe SLE flares in the last 5 months of LBSL02.~2. Had an SLE flare during the last 30 days of LBSL02 and through the 1st dose in LBSL99.~3. Used any of the following prohibited medications during their participation in LBSL02:~   * Other investigational agents.~  * Biologic therapeutic agents: adalimumab (Humira™), etanercept (Enbrel™), infliximab (Remicade™), and rituximab (Rituxan™).~  * Intravenous cyclophosphamide.~  * Corticosteroids \>100 mg/day prednisone equivalent for reasons other than severe SLE flare.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Belimumab 10 mg/kg (Type: EXPERIMENTAL): Belimumab 10 mg/kg IV over one hour every 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).